The randomized, double-blind study is designed to evaluate the safety and efficacy of AMMONUL
versus standard of care in hospitalized adults.
This funding, in addition to the recently announced $40 million in Series B financing, will enable the Company to advance clinical trials of GT4P for potential use in urea cycle disorder (UCD) and hepatic encephalopathy (HE) and AMMONUL
for potential use in acute HE.
Hyperion recently announced their strategic collaboration with Medicis through which the Company will immediately begin promotion of the only currently FDA approved drugs for the treatment of UCD (AMMONUL
and BUPHENYL) and continue developing AMMONUL
for acute hepatic encephalopathy (HE) and a compound referred to as GT4P for chronic UCD and HE.